Glucuronidation of acetaminophen is independent of UGT1A1 promotor genotype

International Journal of Clinical Pharmacology and Therapeutics

Volumn 42, Issue 2, 2004, Pages 73-77

  Rauchschwalbe, Sonja K ^a,b,c   Zuhlsdorf M T ^b   Wensing, G ^b   Kuhlmann, J ^b  

^a UNIVERSITY OF WÜRZBURG   (Germany)

^b BAYER AG   (Germany)

^c NONE   (Germany)

Author keywords

Acetaminophen; Paracetamol; Pharmacogenetics; Polymorphism; Transferase isoform 1A1 (UGT1A1); Uridine diphosphate glucuronosyl

Indexed keywords

BEN U RON; BILIRUBIN; DRUG METABOLITE; GLUCURONOSYLTRANSFERASE; GLUCURONOSYLTRANSFERASE 1A1; PARACETAMOL; PARACETAMOL GLUCURONIDE; UNCLASSIFIED DRUG;

ADULT; ARTICLE; BILIRUBIN BLOOD LEVEL; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE PREDISPOSITION; DRUG METABOLISM; DRUG URINE LEVEL; ENZYME ACTIVITY; GENETIC POLYMORPHISM; GENOTYPE; GILBERT DISEASE; GLUCURONIDATION; HETEROZYGOSITY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN EXPERIMENT; LIVER TOXICITY; MALE; METABOLIC REGULATION; MUTATIONAL ANALYSIS; NORMAL HUMAN; PROMOTER REGION; STATISTICAL ANALYSIS; URINALYSIS; WILD TYPE;

EID: 1242296352     PISSN: 09461965     EISSN: None     Source Type: Journal    
DOI: 10.5414/CPP42073     Document Type: Article

References (16)

1. Beutler E, Gelbart T, Demina A 1998 Racial variability in the UDP-glucuronosyltransferase 1 (UGT1A1) promotor: a balanced polymorphism for regulation of bilirubin metabolism? Proc Natl Acad Sci USA 95: 8170-8174
2. Bock KW, Foster A, Gschaidmeier H, Bruck M, Munzel P, Scharek W, Fournel-Gigleux S, Burchell B 1993 Paracetamol glucuronidation by recombinant rat and human phenol UDP glucuronosyltransferases. Biochem Pharmacol 45: 1809-1814
3. Bosma PJ, Chowdhury JR, Bakker C, Ganda S, DeBoer A, Oostra BA, Lindhout D, Tytgat GNJ, Jansen PLM, Elrerink RPJO, Chowdhury NR 1995 The genetic basis of the reduced expression of bilirubin UDP glucuronosyltransferase 1 in Gilbert's syndrome. N Engl J Med 333: 1171-1175
4. Ciotti M, Marrone A, Potter C, Owens IS 1997 Genetic polymorphism in the human UGT1A6 (planar phenol) UDP glucuronosyltransferase: pharmacological implications. Pharmacogenetics 7: 485-495
5. DeMorais SMF, Wells PG 1988 Deficiency in bilirubin UDP glucuronosyltransferase as a genetic determinant of acetaminophen toxicity. J Pharmacol Exp Ther 247: 323-331
6. DeMorais SMF, Uetrecht JP, Wells PG 1992 Decreased glucuronidation and increased bioactivation of acetaminophen in Gilbert's syndrome. Gastroenterology 102: 577-586
7. Esteban A, Perez-Mateo M 1993 Gilbert's disease: a risk for paracetamol overdosage? J Hepatol 18: 257-258
8. Goicoechea AG, López de Alda MJ, Vila-Jato JL 1995 A validated high-performance liquid chromatographic method for the determination of paracetamol and its major metabolites in urine. J Liquid Chrom 18: 3257-3268
9. Iyer L, King CD, Whitington PF, Green MD, Roy SK, Tephly TR, Coffman BL, Ratain MJ 1998 Genetic predisposition to the metabolism of irinotecan (CPT-11). Role of uridine diphosphate glucuronosyltransferase isoform 1A1 in the glucuronidation of its active metabolite (SN-38) in human liver microsomes. J Clin Invest 101: 847-854
10. Iyer L, Hall D, Dos S, Mortell MA, Ramírez J, Kim S, DiRienzo A, Ratain MJ 1999 Phenotype-genotype correlation of in vitro SN-38 (active metabolite of irinotecan) and bilirubin glucuronidation in human liver tissue with UGT1A1 promotor polymorphism. Clin Pharm Ther 65: 576-582
11. Lampe JW, Bigler J, Horner NK, Potter JD 1999 UDP glucuronosyltransferase (UGT1A1*28 and UGT1A6*2) polymorphisms in Caucasians and Asians: relationships to serum bilirubin concentrations. Pharmacogenetics 9: 341-349
12. Nelson SD 1990 Molecular mechanisms of the hepatotoxicity caused by acetaminophen. Semin Liver Dis 10: 267-278
13. Rauchschwalbe SK, Zühlsdorf MT, Schühly U, Kuhlmann J 2002 Predicting the risk of sporadic elevated bilirubin levels and diagnosing Gilbert's syndrome via genotyping the UGT1A1*28 promoter polymorphism. Int J Clin Pharmacol Ther 40: 233-240
14. Ullrich D, Sieg A, Blume R, Bock KW, Schröter W, Bircher J 1987 Normal pathways for glucuronidation, sulphatation and oxidation of paracetamol in Gilbert's syndrome. Eur J Clin Invest 17: 237-240
15. Wasserman E, Myara A, Lokiec F, Goldwasser F, Trivin F, Mahjoubi M, Misset JL, Cvitkovic E 1997 Severe CPT-11 toxicity in patients with Gilbert's syndrome: two case reports. Ann Oncol 8: 1049-1051
16. de Wildt SN, Kearns GL, Leeder JS, van den Anker JN 1999 Glucuronidation in humans. Pharmacogenetic and developmental aspects. Clin Pharmacokinet 36: 439-452